I-XNK Therapeutics AB namuhla imemezele ukuthi isiguli sokuqala selashwe ocwaningweni lomtholampilo lweSigaba II kusetshenziswa umuthi ohamba phambili we-XNK we-autologous natural killer (NK) osekwe kumaseli ngokuhambisana ne-Sanofi anti-CD38 antibody Sarclisa (Isatuximab).
"Ukuthola isiguli sokuqala selashwe ngamaseli e-NK kulolu cwaningo lomtholampilo kuyingqopha-mlando ebalulekile ekuthuthukisweni komtholampilo komuntu ohamba phambili wesidakamizwa," kusho u-Johan Aschan, i-CMO ye-XNK Therapeutics. “Ucwaningo luqhubeka kahle, futhi sibheke ngabomvu imiphumela.”
Ucwaningo lwamanje olusungulwe, oluvulekile, olungahleliwe, olulawulwayo, lweSigaba II ISA-HC-NK (EudraCT: 2020-000994-26) luqhathanisa umuthi ohamba phambili we-XNK ohlanganiswe ne-Sanofi anti-CD38 antibody Isatuximab ne-Isatuximab iyodwa njengendlela yokwelapha yokuhlanganisa elandelayo. i-autologous stem cell transplantation ezigulini ezine-myeloma eminingi esanda kutholakala. Ucwaningo lomtholampilo lwenzeka e-Karolinska University Hospital endaweni yaso yase-Huddinge futhi luhlanganisa ingqikithi yeziguli ezingama-60 neziguli ezingama-30 engalweni ngayinye yokwelashwa.
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- “Having the first patient treated with NK cells in this clinical study is an important milestone in the clinical development of our leading drug candidate,”.
- The clinical study takes place at the Karolinska University Hospital at its Huddinge site and encompasses at total of 60 patients with 30 patients in each treatment arm.
- I-XNK Therapeutics AB namuhla imemezele ukuthi isiguli sokuqala selashwe ocwaningweni lomtholampilo lweSigaba II kusetshenziswa umuthi ohamba phambili we-XNK we-autologous natural killer (NK) osekwe kumaseli ngokuhambisana ne-Sanofi anti-CD38 antibody Sarclisa (Isatuximab).
